Upper Tract Urothelial Cancer
Steba Biotech S.A. focuses its clinical research on low-grade upper tract urothelial cancer, with particular attention to tumors arising in the renal pelvis, calyces, and ureter. The sponsor’s trial activity centers on evaluating treatment approaches for disease control within the upper urinary tract.
- Upper tract urothelial carcinoma
- Renal pelvis tumors
- Ureteral malignancy
The clinical program reflects interest in organ-preserving management of localized urothelial disease in the upper urinary tract.
Photodynamic and Light-Activated Therapy
The sponsor is active in vascular targeted photodynamic therapy, a therapeutic domain that uses light-activated treatment principles in oncology. Its research activity is linked to TOOKAD (padeliporfin) and its application in localized urinary tract tumors.
- Photodynamic therapy
- Vascular targeted treatment
- Light-activated oncology
This area highlights a specific interest in non-surgical local tumor treatment strategies for urologic cancer.
Urologic Oncology
Steba Biotech’s research landscape is concentrated in urologic oncology, particularly cancers affecting the urinary collecting system. The funded trial activity points to a therapeutic focus on preserving function while addressing malignant lesions in anatomically sensitive sites.
- Urinary tract cancer
- Localized tumor management
- Organ-sparing approaches
The sponsor’s clinical interest is narrowly defined around malignancies of the upper urinary tract rather than broader oncologic indications.
